µÏÍþ¹ú¼Ê

µÏÍþÖƵÏÍþ¹ú¼Ê µÏÍþÖƵÏÍþ¹ú¼Ê

¼ò ¤™
  • ¼ò
  • ·±
  • EN
¤œ
Ïà¹ØÁ´½Ó
  • ½­ËÕºÀÉ­µÏÍþ¹ú¼ÊÒµ¼¯ÍÅÓÐÏÞ¹«Ë¾¥Y
ÐÂÎÅ·¢²¼
Press Release
Ê×Ò³  >  ÐÂÎÅÖÐÐÄ  >  ÐÂÎÅ·¢²¼
2025 ASH | µÏÍþÖƵÏÍþ¹ú¼Ê´´ÐµÏÍþ¹ú¼ÊºÀɭ꿸£?Я¶àÏî´´ÐÂÑо¿ÁÁÏ࣬Ϊ¹ú¼ÊѪҺÖ×ÁöÇ°ÑØÑо¿×¢ÈëÖйú´´Ð¶¯ÄÜ
·¢²¼ÈÕÆÚ£º2025/12/19
×ÖºÅ

µÚ67½ìÃÀ¹úѪҺѧ»á£¨ASH£©Äê»áÓÚµ±µØʱ¼ä2025Äê12ÔÂ6ÈÕ-9ÈÕÔÚÃÀ¹ú°ÂÀ¼¶àÊ¢´óÕÙ¿ª¡£×÷ΪȫÇòѪҺѧÁìÓòµÄ¶¥¼âѧÊõÊ¢»á£¬±¾´Î´ó»á»ã¾Ûº£ÄÚÍâר¼ÒѧÕߣ¬·ÖÏí×îÐÂÁÙ´²½øÕ¹ÓëÑо¿Í»ÆÆ¡£µÏÍþÖƵÏÍþ¹ú¼Ê´´ÐµÏÍþ¹ú¼ÊºÀɭ꿸£?£¨¼×»ÇËá·úÂíÌæÄáƬ£¬ÒÔϼò³Æ·úÂíÌæÄᣩЯһÏîÑо¿ÈëÑ¡±¾½ì´ó»á¡£×÷Ϊ´ó»áµÄÖØÒª»·½Ú£¬Å·ÖÞ°×Ѫ²¡Íø£¨ELN£©ÂýÐÔËèÐÔ°×Ѫ²¡£¨CML£©¹¤×÷×éÔç²Í»áҲͬÆÚ¾ÙÐУ¬Î§ÈÆCMLµÄÖÎÁƲßÂÔ¡¢Í£µÏÍþ¹ú¼Ê³¢ÊÔ¡¢µÏÍþ¹ú¼ÊÎïÑ¡ÔñµÈÈȵãÒéÌâÕ¹¿ªÉîÈë̽ÌÖ¡£ÔÚ±¾´ÎELN CML¹¤×÷×éÔç²Í»áÉÏ£¬·úÂíÌæÄá´øÀ´ÁËÁ½¸öÖ÷Ìâ·ÖÏí£¬³ÖÐøΪ¹ú¼ÊCMLѧÊõÑо¿×¢ÈëÖйú´´Ð¶¯ÄÜ¡£



ASHÕªÒª±àºÅ£ºabs25-7668


·úÂíÌæÄá¶Ô±ÈÄáÂåÌæÄá×÷ΪÂýÐÔÆÚÂýÐÔËèÐÔ°×Ѫ²¡µÄÒ»ÏßÖÎÁÆ£ºÒ»ÏîÇãÏòÆÀ·ÖÆ¥ÅäµÄ¶ÓÁÐÑо¿[1]

 Ö÷ÒªÑо¿ÕߣºÐíÄÈ£¨ÄÏ·½Ò½¿Æ´óѧÄÏ·½Ò½Ôº£©

¸ÃÑо¿ÀûÓöàÖÐÐÄÊý¾Ý²¢²ÉÓÃÇãÏòÆÀ·ÖÆ¥Åä·¨£¬¶Ô·úÂíÌæÄáºÍÄáÂåÌæÄá×÷ΪÂýÐÔËèϵ°×Ѫ²¡ÂýÐÔÆÚ»¼Õß(CML-CP)Ò»ÏßÖÎÁÆ·½°¸µÄÁÆЧ£¨°üÀ¨»º½âÂʺÍÎÞ½øÕ¹Éú´æÆÚ£©¼°°²È«ÐÔ£¨°üÀ¨²»Á¼Ê¼þ¡¢¼ÁÁ¿½µµÍºÍÖÎÁÆÖжÏÂÊ£©½øÐÐÁ˱ȽϷÖÎö¡£Ñо¿³õʼÄÉÈëÁË315ÃûÐÂÕï¶ÏCML-CP»¼Õߣ¬·Ö±ð½ÓÊÜ·úÂíÌæÄáºÍÄáÂåÌæÄáÖÎÁÆÖÎÁÆ¡£¾­¹ý1:1µÄÇãÏòÆÀ·ÖÆ¥Åä·ÖÎöºó£¬·úÂíÌæÄá×éºÍÄáÂåÌæÄá×é¸÷ÄÉÈë135Ãû»¼Õß¡£Á½×黼ÕßµÄÖÐλÄêÁä¾ùΪ39Ë꣬»ùÏßÌØÕ÷¾ùºâ¡£

½á¹ûÏÔʾ£¬ÔÚ6¸öÔ¡¢12¸öÔºÍ24¸öÔÂʱ£¬·úÂíÌæÄá×éºÍÄáÂåÌæÄá×éµÄÍêȫϸ°ûÒÅ´«Ñ§·´Ó¦£¨CCyR£©¡¢Ö÷Òª·Ö×Óѧ·´Ó¦£¨MMR£©¡¢·Ö×Óѧ·´Ó¦4.0£¨MR4.0£©ºÍ·Ö×Óѧ·´Ó¦4.5£¨MR4.5£©µÄÀÛ»ý·¢ÉúÂʾùÎÞͳ¼ÆѧÏÔÖø²îÒ졣Ȼ¶ø£¬Á½ÖÖTKIµÄ¶¾ÐÔÆ×ÌØÕ÷´æÔÚÃ÷ÏÔ²»Í¬¡£ÄáÂåÌæÄáÖ÷Òª±íÏÖΪµ¨ºìËغÍÖ¬·¾Ã¸Éý¸ß£¬·úÂíÌæÄáÔòÖ÷ÒªÒýÆð¸¹ÐººÍÉö¹¦ÄÜË𺦡£

¸ÃÑо¿Í¨¹ýÕæʵÊÀ½çµÄÁÙ´²Êý¾Ý£¬Ö¤ÊµÁË·úÂíÌæÄáºÍÄáÂåÌæÄá×÷ΪCML-CPÒ»ÏßÖÎÁÆ·½°¸µÄ×ÜÌåÁÆЧÏ൱£¬µ«Æ䰲ȫÐÔÌØÕ÷´æÔÚ²îÒ졣ΪÁÙ´²Ò½ÉúÖƶ¨¸öÌ廯ÖÎÁÆ·½°¸¡¢¾«×¼Æ½ºâÁÆЧÓ밲ȫÐÔÌṩÁ˸ßÖÊÁ¿µÄѭ֤ҽѧ֤¾Ý£¬½øÒ»²½·á¸»ÁË CML-CP Ò»ÏßÖÎÁƵľö²ßÒÀ¾Ý¡£

ELN CML Ôç²Í»á


µ±µØʱ¼ä2025Äê12ÔÂ7ÈÕ¾ÙÐеÄELN CMLÔç²Í»áÓÉR¨¹diger Hehlmann½ÌÊÚ¿ªÄ»Ö´Ç£¬»ã¾ÛÁËÈ«ÇòCMLÁìÓò¶¥¼âר¼ÒѧÕߣ»Ôç²Í»áÉèÖÃÁËÁ½Ïî·úÂíÌæÄáµÄ¿ÚÍ·»ã±¨£¬·Ö±ðΧÈÆÒ»ÏßÖÎÁÆÓ¦ÓᢺóÏßÖÎÁƼÛÖµµÈÇ°ÑØÒéÌâÕ¹¿ªÉî¶È½â¶ÁÓë½»Á÷£¬ÎªÓë»áÕß¹¹½¨¸ßÖÊÁ¿µÄѧÊõ¶Ô»°Æ½Ì¨¡£

¡ñ ·úÂíÌæÄá×éÒ»ÏßÖÎÁÆÁÆЧ¿Ï¶¨£º»¼Õß12¸öÔÂMMRÂÊ´ï85.1%£¬24¸öÔÂÖÎÁÆʧ°ÜÂʽöΪ9.9%£¬ÇÒµÏÍþ¹ú¼ÊÎïת»»ÂÊÏÔÖø¸üµÍ£¬½ö5.9%¡£ÕâһϵÁÐÊý¾Ý³ä·ÖÌáʾ£¬·úÂíÌæÄáÊÇCMLÂýÐÔÆÚ»¼ÕßÒ»ÏßÖÎÁƵÄÓÅÑ¡·½°¸Ö®Ò»£¬¼ÈÄÜÖúÁ¦»¼Õß¿ìËÙ´ï³ÉÖ÷Òª·Ö×Óѧ·´Ó¦Ä¿±ê£¬Ó־߱¸¸üÓŵÄÖÎÁÆÄÍÊÜÐÔ£¬Îª»¼Õߵij¤Æڹ淶ÖÎÁÆÓë¼²²¡¹ÜÀíµì¶¨¼áʵ»ù´¡2¡£

¡ñ ·úÂíÌæÄáÔÚ¼ÈÍù½ÓÊܹýTKIÖÎÁƵÄÖйúCMLÂýÐÔÆÚ»¼ÕßÖУ¬Õ¹ÏÖ³öÁ¼ºÃµÄÁÆЧÓ밲ȫÐÔ£»ÓÈÆäÔÚ¶þÏßÖÎÁÆÖУ¬·úÂíÌæÄá¿É´øÀ´½Ï¸ßµÄ»º½âÂÊ£¬¶Ô¼ÈÍùδ·¢Éú¶þ´úTKIÄ͵ÏÍþ¹ú¼ÊµÄ»¼Õß»ñÒæ¸üΪÏÔÖø£¬Îª¸ÃÀ໼ÕßÌṩÁ˸üÓŵÄÖÎÁÆÑ¡Ôñ3¡£


²Î¿¼ÎÄÏ×£º

[1]Na Xu, et al. ASH 2025, abs25-7668: Flumatinib versus nilotinib as first-line therapy for chronic myeloid leukemia in chronic phase: A propensity score-matched cohort study.

[2]Lei Y, et al. Real-world comparison of flumatinib and nilotinib as first-line therapy for patients with chronic phase chronic myeloid leukemia: a multicenter retrospective study. Ther Adv Med Oncol. 2025 Apr 29;17:17588359251335905. 

[3]Yang Y, et al. Safety and efficacy of flumatinib as later-line therapy in patients with chronic myeloid leukemia. Haematologica. 2024 Dec 1;109(12):3965-3974. 



¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê

µÏÍþÖƵÏÍþ¹ú¼ÊÊÇÖйúÁìÏȵĴ´ÐÂÇý¶¯ÐÍÖƵÏÍþ¹ú¼ÊÆóÒµ£¬ÏÂÊôºÀÉ­µÏÍþ¹ú¼ÊÒµ¡¢³£Öݺã°îµÏÍþ¹ú¼ÊÒµ¡¢µÏÍþÉúÎïÒ½µÏÍþ¹ú¼ÊµÈ×Ó¹«Ë¾£¬ÒÔ¡¸³ÖÐø´´Ð£¬Ìá¸ßÈËÀàÉúÃüÖÊÁ¿¡¹ÎªÊ¹Ãü£¬Öصã¹Ø×¢¿¹Ö×Áö¡¢¿¹¸ÐȾ¡¢ÖÐÊàÉñ¾­ÏµÍ³¡¢´úл¼°×ÔÉíÃâÒßµÈÖØ´ó¼²²¡ÖÎÁÆÁìÓò¡£½ØÖÁÄ¿Ç°£¬¹«Ë¾ÔÚÖйú²úÉúÏúÊÛÊÕÈëµÄ´´ÐµÏÍþ¹ú¼Ê¹²Æ߿´´ÐµÏÍþ¹ú¼ÊÊÕÈëÕ¼±È³¬°Ë³É£¬²¢½¨Á¢Á˷ḻµÄÑз¢¹ÜÏß¡£µÏÍþÖƵÏÍþ¹ú¼ÊÁ¬Ðø¶àÄêλ¾ÓÈ«ÇòÖƵÏÍþ¹ú¼ÊÆóÒµ°ÙÇ¿¡¢ÖйúÒ½µÏÍþ¹ú¼ÊÑз¢²úÆ·Ïß×î¼Ñ¹¤ÒµÆóҵǰÈýÇ¿£¬Êǹú¼ÒÖصã¸ßм¼ÊõÆóÒµ¡¢¹ú¼Ò¼¼Êõ´´ÐÂʾ·¶ÆóÒµ¡£µÏÍþÖƵÏÍþ¹ú¼ÊÓÚ2019Äê6ÔÂÔÚÏã¸ÛÁª½»Ëù¹ÒÅÆÉÏÊУ¨¹ÉƱ´úÂ룺03692.HK£©¡£

ÃâÔðÉùÃ÷

±¾ÎĽö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬·Ç¹ã¸æÓÃ;¡£µÏÍþÖƵÏÍþ¹ú¼Ê²»ÍƼöÈκÎδ»ñÅúµÏÍþ¹ú¼ÊƷʹÓúÍ/»òδ»ñÅúÊÊÓ¦Ö¢ÓõÏÍþ¹ú¼Ê£¬Ò಻¶ÔÈκεÏÍþ¹ú¼ÊÆ·ºÍ/»òÊÊÓ¦Ö¢×÷ÍƼö¡£±¾ÎÄÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£Ò½ÁÆÎÀÉúרҵÈËÊ¿×÷³öµÄÈκÎÓëÖÎÁÆÓйصľö¶¨Ó¦¸ù¾Ý»¼ÕߵľßÌåÇé¿ö²¢×ñÕÕµÏÍþ¹ú¼ÊƷ˵Ã÷Êé¡£ÈçÐèÁ˽⹫˾ÈκβúÆ·¡¢Ò½ÁÆ»ò¼²²¡µÄÏà¹ØÐÅÏ¢£¬ÇëÎñ±Ø×ÉѯҽÁÆÎÀÉúרҵÈËÊ¿¡£

Ç°Õ°ÐÔ˵Ã÷

±¾ÐÂΟåÖ¼ÔÚÌṩ¹ØÓÚµÏÍþÖƵÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾¼°Æ丽Êô¹«Ë¾£¨°üÀ¨Æä×Ó¹«Ë¾£¬Í³³ÆΪ¡°µÏÍþÖƵÏÍþ¹ú¼Ê¡±£©µÄÐÅÏ¢¡£Ëü²»¹¹³É¶ÔµÏÍþÖƵÏÍþ¹ú¼Ê»òÈκÎͶ×ʽ¨ÒéµÄÐÅÏ¢Åû¶¡£±¾ÐÂΟå°üº¬µÄÐÅÏ¢¿ÉÄÜ°üÀ¨ÓëµÏÍþÖƵÏÍþ¹ú¼ÊÒµÎñºÍ²úÆ·Ç°¾°¡¢¼Æ»®¡¢ÐÅÄî¡¢Ô¤ÆںͲßÂÔÏà¹ØµÄÇ°Õ°ÐÔÉùÃ÷¡£ÕâЩÉùÃ÷ÊÇ»ùÓÚÍƲâÐÔ¼ÙÉèµÄÔ¤²â£¬²¢²»±£Ö¤Î´À´µÄ±íÏÖ¡£ËüÃÇÊܵ½ÖîÈç¿Æѧ¡¢ÉÌÒµ¡¢ÕþÖΡ¢¾­¼Ã¡¢²ÆÎñ¡¢·¨ÂÉÒòËØÒÔ¼°¾ºÕù»·¾³ºÍÉç»áÌõ¼þµÈ·çÏպͲ»È·¶¨ÐÔµÄÓ°Ï죬ÕâЩÒòËغܶ඼ÊǵÏÍþÖƵÏÍþ¹ú¼ÊÎÞ·¨¿ØÖÆÇÒÄÑÒÔÔ¤²âµÄ£¬Òò´Ëʵ¼Ê½á¹û¿ÉÄÜÓë´Ë´¦ËùÊöÓÐÏÔÖø²îÒ죬ÇÒ¹ýÈ¥µÄ֤ȯ¼Û¸ñÇ÷ÊƲ»Ó¦×÷ΪδÀ´ÐÐÇéµÄÖ¸µ¼¡£Òò´Ë£¬Í¶×ÊÕßÔÚʹÓÃÕâЩÐÅÏ¢½øÐÐͶ×ʾö²ßʱӦ½÷É÷ÐÐÊ¡£¡°ÖÂÁ¦ÓÚ¡±¡°Ô¤ÆÚ¡±¡°ÏàÐÅ¡±¡°Ô¤²â¡±¡°Òâͼ¡±¡°Ô¤¼Æ¡±¡°¿ÉÄÜ¡±¡°½«¡±¡°Ó¦¸Ã¡±¡°¼Æ»®¡±¡°¼ÌÐø¡±¡°Ä¿±ê¡±¡°¿¼ÂÇ¡±¡°¹À¼Æ¡±¡°Ö¸µ¼¡±¡°Ç±ÔÚ¡±¡°×·Çó¡±ÒÔ¼°ÓÚÈκÎδÀ´¼Æ»®¡¢Ðж¯»òʼþµÄÌÖÂÛÖÐʹÓõÄÀàËÆ´ÊÓïºÍÊõÓ¾ù±íʾǰհÐÔÉùÃ÷¡£µÏÍþÖƵÏÍþ¹ú¼Ê²»³Ðŵ»ò±£Ö¤Ç°Õ°ÐÔÐÅÏ¢µÄ׼ȷÐÔ¡¢¼°Ê±ÐÔ»òÍêÕûÐÔ£¬²¢ÇÒ²»³Ðµ£¸üлòÐÞ¶©ÕâЩǰհÐÔÉùÃ÷µÄÒåÎñ¡£ÎÞÂÛÊǵÏÍþÖƵÏÍþ¹ú¼Ê»¹ÊÇÆäÈκζ­Ê¡¢Ô±¹¤»ò´úÀíÈË£¬¾ù²»¶ÔÈκÎÖ¤Ã÷²»×¼È·»òÎÞ·¨ÊµÏÖµÄÇ°Õ°ÐÔÉùÃ÷¸ºÔð£¬Ò²²»¶ÔÒòÒÀÀµ±¾ÐÂΟåÖÐÌṩµÄÐÅÏ¢¶ø²úÉúµÄÈκÎËðʧ»òË𺦸ºÔ𣬰üÀ¨µ«²»ÏÞÓÚÖ±½Ó¡¢Å¼È»¡¢¼ä½Ó»ò³Í·£ÐÔµÄË𺦡£

¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿